Tenderwize
Retour à la recherche

Open House Biologic Discount Agreements 2025-18 - Insulin glargin (100 U/ml)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 369 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-18 - Insulin glargin (Wirkstärke: 100 U/ml)

40/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

60 / 100

Facteurs de risque

The procedure is not a public procurement subject to procurement review; disputes go to social courts. Legal recourse i...

No estimated value – potential revenue is unknown. Contract may attract many participants, diluting volume.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Execution of a discount agreement (Rabattvertrag) for Insulin glargin (100 U/ml) with participating health insurance funds.
  • Supply of the pharmaceutical product under standardized conditions for up to 24 months.
Afficher le résumé complet

This is an Open-House procedure for pharmaceutical discount agreements (Rabattverträge) on Insulin glargin (100 U/ml) with multiple German statutory health insurance funds led by Techniker Krankenkasse. The procedure is open to all qualified pharmaceutical entrepreneurs who meet the eligibility criteria. The contract term is up to 24 months starting from 1 September 2025 (with a later start for hkk on 1 October 2025) and ending no later than 31 August 2027. No estimated value is provided. The award is based solely on meeting eligibility requirements, not on competition. Electronic submission is not allowed via the portal; contracts must be submitted by email (with qualified electronic signature) or by post.

Risques

The procedure is not a public procurement subject to procurement review; disputes go to social courts. Legal recourse i...

No estimated value – potential revenue is unknown. Contract may attract many participants, diluting volume.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.
  • Must hold a valid marketing authorization for the product in Germany or be entitled to place it on the market under own name.
  • Seat must be in Germany, another EU member state, or an EEA state.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Biologic Discount Agreements 2025-18 - Insulin glargin (100 U/ml)

Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Insulin glargin (Wirkstärke: 100 U/ml) im Rahmen eines Open-House-Verfahrens. The lot covers nationwide supply of Insulin glargin with a maximum contract duration of 24 months.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 30, 2027

Détails de la procédure

Date de publication
09 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
372143-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3